Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Poly (ADP-ribose) polymerase (PARP-)remmers bij het ovariumcarcinoom
sep 2018 | Gynaecologische oncologie